Bradley L. Campbell - Mar 1, 2023 Form 4 Insider Report for AMICUS THERAPEUTICS, INC. (FOLD)

Role
President & CEO, Director
Signature
/s/ Christian Formica, Attorney-in-Fact
Stock symbol
FOLD
Transactions as of
Mar 1, 2023
Transactions value $
-$236,196
Form type
4
Date filed
3/3/2023, 04:42 PM
Previous filing
Feb 3, 2023
Next filing
Mar 17, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FOLD Common Stock Options Exercise $28.7K +11.7K +1.38% $2.45* 857K Mar 1, 2023 Direct
transaction FOLD Common Stock Sale -$203K -15.5K -1.8% $13.12 841K Mar 1, 2023 Direct F1, F2
transaction FOLD Common Stock Sale -$62.1K -4.54K -0.54% $13.68 837K Mar 1, 2023 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FOLD Stock Options (right to buy) Options Exercise $0 -11.7K -27.71% $0.00 30.5K Mar 1, 2023 Common Stock 11.7K $2.45 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $12.62 to $13.61 inclusive. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 This price is the weighted average price for the transactions reported on this line. The prices for the transactions reported on this line range from $13.62 to $13.82. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 All of the options were fully vested and exercisable as of the transaction date.